Evolution of the Average Target: Bristol-Myers Squibb Company

Evolution of the Target Price: Bristol-Myers Squibb Company

Changes in Analyst Recommendations: Bristol-Myers Squibb Company

ef92f304d6451.zA6HHyE7Vk2wh6HjdKDX3z_bQHFDnUanHiuqX4M26hI.vjjBckJSJCLIwMiyP9SmtWaJL0UA1S_pXHThHK5GvyKdSOFFfl4DCN3Uxg~10d35372b9424f1f5deb6c09db618c10
03-09 Global markets live: Live Nation, Eli Lilly, Amazon, Microsoft, ABB… Zonebourse
02-25 Bristol-Myers Squibb's Risk/Reward Profile Balanced, RBC Says MT
02-25 RBC Initiates Bristol-Myers Squibb at Sector Perform With $60 Price Target MT
02-25 Berenberg Lifts Price Target on Bristol-Myers Squibb to $60 From $57, Keeps Hold Rating MT
02-23 Piper Sandler Adjusts Price Target on Bristol-Myers Squibb to $75 From $66, Maintains Overweight Rating MT
02-20 Daiwa Securities Adjusts Price Target on Bristol-Myers Squibb to $62 From $43, Maintains Neutral Rating MT
02-20 Analyst recommendations: Walmart, Alphabet, Deere & Company, Stellantis, Workday… Zonebourse
02-06 Wells Fargo Adjusts Bristol-Myers Squibb PT to $60 From $55, Maintains Equal Weight Rating MT
02-06 Citigroup Adjusts Bristol-Myers Squibb PT to $64 From $60, Maintains Neutral Rating MT
02-06 JPMorgan Adjusts Bristol-Myers Squibb PT to $67 From $65, Maintains Overweight Rating MT
02-06 Morgan Stanley Lifts Price Target on Bristol-Myers Squibb to $40 From $37, Keeps Underweight Rating MT
02-06 Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $61 From $57, Maintains Neutral Rating MT
02-06 Leerink Partners Adjusts Price Target on Bristol-Myers Squibb to $67 From $60, Maintains Outperform Rating MT
02-06 Guggenheim Raises Price Target on Bristol-Myers Squibb to $72 From $62, Maintains Buy Rating MT
02-05 JPMorgan Raises Bristol-Myers Squibb Price Target to $67 From $65 MT
01-29 TD Cowen Adjusts Bristol-Myers Squibb Price Target to $60 From $54, Maintains Hold Rating MT
01-28 Piper Sandler Adjusts Bristol-Myers Squibb Price Target to $66 From $62, Maintains Overweight Rating MT
01-27 Citigroup Adjusts Price Target on Bristol-Myers Squibb to $60 From $53, Maintains Neutral Rating MT
01-26 BMO Capital Adjusts PT on Bristol-Myers Squibb to $55 From $47, Maintains Market Perform Rating MT
01-13 Leerink Partners Adjusts Price Target on Bristol-Myers Squibb to $60 From $54, Maintains Outperform Rating MT
01-09 Scotiabank Adjusts Price Target on Bristol-Myers Squibb to $60 From $53, Maintains Sector Perform Rating MT
01-07 UBS Upgrades Bristol-Myers Squibb to Buy From Neutral, Lifts Price Target to $65 From $46 MT
12-17 Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $65 From $52, Maintains Hold Rating MT
12-15 Bristol-Myers Squibb Seen as Attractive Ahead of 2026 Pipeline Catalysts, BofA Says MT
12-15 BofA Securities Upgrades Bristol-Myers Squibb to Buy From Neutral, $61 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+3.97%
+21.71%
-1.93%
+9.3%
+10.54%
+13.32%
-2.7%
+9.48%
-7.31%
+7.26%
Average +6.36%
Weighted average by Cap. +8.81%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
59.98USD
Average target price
62.36USD
Spread / Average Target
+3.97%
High Price Target
75.00USD
Spread / Highest target
+25.04%
Low Price Target
40.00USD
Spread / Lowest Target
-33.31%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

RBC Capital Markets
Berenberg Bank
Piper Sandler
Daiwa Securities
Morgan Stanley
Guggenheim
Leerink Partners
Goldman Sachs
JPMorgan Chase
Citigroup
Wells Fargo Securities
TD Cowen
BMO Capital
Scotiabank
UBS
Deutsche Bank Securities
BofA Securities
HSBC
Cantor Fitzgerald
Rothschild & Co Redburn
Redburn Atlantic
Jefferies & Co.
Truist Securities
Bernstein
Barclays
Wolfe Research
Societe Generale
Redburn
William Blair & Co.
Credit Suisse
Atlantic Equities
Raymond James
Argus
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
59.98USD
Average target price
62.36USD
Spread / Average Target
+3.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. BMY Stock
  4. Consensus Bristol-Myers Squibb Company
SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW